CELIX PHARMA LTd

This page summarises award records that name this supplier and the public buyers listed alongside it. Published names are joined when identifiers or close name matches support the link.

Award history

Published records by year

Each row counts award records linked to this supplier. A single procurement can produce more than one award.

Annual award records and published value assigned to this supplier
Year	Awards	Value counted	Values not counted
2026	3	Value not published	3
2025	1	Value not published	1
2024	2	Value not published	2

Buyer relationships

Buyer relationships by value counted

Ranked by published value assigned to this supplier, then by award count.

SupplierCELIX PHARMA LTd

Source records

Published awards

20 records linked to this supplier.

NHS Framework Agreement for Branded Medicines - Proprietary Category Tender
Buyer: NHS England
End date in notice
30 Apr 2029
Value shown in notice
£1,241,520,444Whole award value; not assigned to one supplier
Official source
Open the official Contracts Finder notice for NHS Framework Agreement for Branded Medicines - Proprietary Category Tender
About this figure
- This award names more than one supplier but does not divide the published value between them. The figure is shown for context and is not assigned to one supplier.
View record references
Source
Contracts Finder
Award or lot reference
ocds-b5fd17-1063d704-a8da-4ec0-b11c-5b9fec849d60 / ocds-b5fd17-1063d704-a8da-4ec0-b11c-5b9fec849d60-1
Transitional Drugs 7
Buyer: Velindre University NHS Trust

CELIX PHARMA LTd

Published records by year

Buyer relationships by value counted

Published awards

NHS Framework Agreement for Branded Medicines - Proprietary Category Tender

Transitional Drugs 7

Lot 2 - CM/PHG/23/5699/02 CM/PHG/23/5699/02 Hospital only products

NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin

NHS National Framework for Transition Products (Nintedanib and Dalbavancin)

Lot 1 - CM/PHG/23/5699/01 Oral (plus non-parenteral) products

NHS National Framework for Transition products commencing 1 October 2024

NHS National Framework for Transition products commencing 1 May 2024

Range of Generic Cancer Medicines (single supplier)

Icatibant Solution for Injection

Direct Acting Oral Anticoagulants (DOACs)

NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1 May 2025

Transitional Drugs 3

Wave 15b - Hospital Only (Housekeeping) All regions

Wave 15b - Hospital Only DCE & DSW regions

NP49425 Generic and Biosimilar Transition Medicines

Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines

Apremilast

Cardiovascular and Respiratory Medicines

Nintedanib